Policy on Gene Transfer Research Trials

Date: December 19, 2011  Policy ID: 2.100  Status: Final

Contact Office:
Assistant Dean for Research
University of Virginia School of Medicine
PO Box 800793
Charlottesville, VA 22908
Phone: 434-924-8789
Fax: 434-982-0874

Oversight Executive:
Senior Associate Dean for Research
University of Virginia School of Medicine
PO Box 800793
Charlottesville, VA 22908
Phone: 434-924-243-7088
Fax: 434-982-0874

Applies to: Any faculty member who wishes to conduct research involving the deliberate transfer of recombinant DNA, (or DNA or RNA derived from recombinant DNA), into one or more human research participants at the University of Virginia.

Reason for Policy: This policy will ensure that any research involving the deliberate transfer of recombinant DNA into a human subject will be carried out in accordance with University and Federal policies.

Policy

This policy applies to experiments involving the deliberate transfer of recombinant DNA, (or DNA or RNA derived from recombinant DNA), into one or more human research participants at the University of Virginia.

Oversight of gene transfer research trials is regulated at the Federal level by the National Institutes of Health (NIH), Office of Biotechnology Activities (OBA)/Recombinant DNA Advisory Committee (RAC). All proposed study protocols must be submitted to the OBA in accordance with Appendix M of "NIH Guidelines: Recombinant DNA and Gene Transfer," (see procedures section). Final approval of all gene transfer research trials at the University of Virginia is the responsibility of the Institutional Review Board – Health Sciences Research (IRB – HSR), and the Institutional Biosafety Committee (IBC).
The IRB-HSR will:
- Verify that the consent form meets all federal regulations according to 45CFR46 and 21CFR50.
- Verify that all appropriate information as outlined in Appendix M of the RAC application is included in the protocol and consent form.
- Verify that all items as suggested by the IBC and RAC are included in the consent form.
- Verify that complete disclosure of any conflict of interest is noted in the consent form.
- Confirm that approval from all other required review committees or bodies have been obtained. A representative from each required committee or body may be present at the IRB-HSR meeting when final approval is given. If a representative is unable to attend, a written approval from them must be submitted for review at the meeting.
- Confirm that key personnel have completed the IRB-HSR research subject protection training.

The IBC will:
- Verify that all aspects of Appendix M of the NIH Guidelines have been addressed by the principal investigator.
- Confirm that key personnel have completed the appropriate biosafety training and that standard operating procedures described in the Biosafety Manual are appropriate and accurately described. Investigators are strongly encouraged to contact the Biosafety Office prior to IBC submission for assistance in creating a satisfactory manual.
- Perform initial and regularly scheduled inspections of clinical facilities where vector distribution, administration and potential subsequent viral shedding may occur to certify the implementation of appropriate work practices and physical controls.
- Assess risks to the environment and the necessity to inform medical care personnel, (e.g., nurses, technicians), of risks, precautions, and recommended health surveillance procedures.
- Verify that Research projects are in compliance with the institution’s health surveillance requirements and data and adverse event reporting requirements.
- Final IBC approval occurs after RAC review.

An ad hoc scientific review committee may be appointed by the SOM VP/Dean to:
- Assess the scientific and medical relevance and merit of the protocol.
- Assess the risk/benefits to subjects and others.
- Review the existing knowledge of the disease state and current therapy, route of administration, dose, and vector virulence.
• Recommend information to be provided to family and other caretakers pertaining to potential risks and precautions to be stated in either a separate document or in the consent form.
• Recommend additional information the IRB-HSR may wish to have included in the consent form pertaining to potential risks to subjects.
• Recommend additional information the IBC may wish to have included in the Biosafety Manual and RAC registration.
• Communicate assessments to the IBC, IRB-HSR, VPR, and PI.

**Additional approvals will be required from the following committees or bodies:**

**UVA School of Medicine Clinical Trials Office (CTO) will:**
• Review the Case Report Forms to verify they are clear, concise and accurate according to the Protocol, Consent Form and Appendix M.
• Verify that procedures are adequate to oversee management of data.
• Review the Monitoring Plan.

If the protocol has an inclusion criterion stating the participants must have cancer and the protocol is NOT sponsored by the NIH, ACS, DOD, NSF or a Cancer Cooperative Group, additional approval may be required by the UVA Cancer Center Protocol Review Committee (PRC). The PRC will:
• Review the scientific relevance of the study in cancer patients.
• Review the quality of the study design, including entry criteria, patient assessment and follow-up, toxicity assessment and dose modification criteria, and biostatistical analytical plan.
• Verify that the Protocol and Consent Form accurately reflect the study as outlined in Appendix M.

**Please Note:**
• No study participants may be enrolled until approval to enroll subjects is granted by the IRB-HSR and the PI/sponsor has obtained an IND from the FDA.
• The mechanism for submittal and approval of study protocols is outlined in the procedures section below.

Additional information regarding the review committees or bodies can be found on their Web sites:
• Institutional Biosafety Committee: [http://ehs.virginia.edu/biosafety/](http://ehs.virginia.edu/biosafety/)
D. PROCEDURES

New Application
2. The protocol must include the information listed in OBA-RAC Appendix M (see Appendix M-I-A), which can be found at: http://oba.od.nih.gov/oba/rac/guidelines_02/APPENDIX_M.htm. Appendix M is part of “NIH Guidelines: Recombinant DNA and Gene Transfer.” The RAC application requires information about the disease under study, vector being used, and nature of the proposal in addition to other items. The NIH review process is open to the public so proprietary information should be withheld. Before writing any SOPs for use during the study, the Biosafety Office should be advised of the proposed work and their help should be sought to prepare the various SOPs and/or Biosafety Manual.
3. Submit the protocol simultaneously to the IRB-HSR, the IBC and the SOM Office for Research. Note that, if applicable, the protocol must be approved by the Cancer Center PRC before it is submitted to the IRB-HSR. The investigator may simultaneously submit the application to OBA for RAC review. If the RAC review indicates areas of concern (e.g., novel vectors, unresolved health concerns, or other potential problems) the protocol will be selected for public review. RAC currently estimates that this public review process will occur for about 10% of submissions.
4. For protocols originating at UVA, the SOM Dean will appoint an ad hoc committee to complete additional scientific reviews of the protocol. The ad hoc committee will send the report of its review to the PI, IBC, IRB, Vice President for Research and if applicable to the PRC. The IBC will review the protocol next, and will send its comments to the IRB prior to that committee’s review.
5. When all reviews have been completed, the PI should submit the revised protocol and consent forms, and responses to comments from all UVA and RAC reviews, to the IRB-HSR, IBC, SOM Office of Research (and if applicable, to the Cancer Center Protocol Review Committee).
6. Personnel from the SOM Clinical Trials Office will review all applicable documents such as case report forms, data and safety monitoring plans, etc.
7. After the IRB-HSR has obtained all applicable approvals, it will notify the Office of the Vice President for Research, who may ask questions, comment, or place a hold on the protocol.
8. Protocol approval will be given by the IRB-HSR only after the IRB-HSR has received approval and all required documentation from all other committees or bodies.
9. Following IRB-HSR approval, the PI will submit the application to the FDA. The PI must notify the IRB-HSR 30 days following the FDA submission if the FDA has not put the Investigational New Drug Application (IND) on clinical hold. At that time, the IRB-HSR will grant approval to enroll subjects.

Monitoring of Protocol After Approval

**Compliance Groups:**

**IRB-HSR:**
- Will require Status Report from PI every 6 months.
- Will review Status Reports along with any additional information provided by the PI.
- Following IBC review and approval, the IRB-HSR will review all modifications made to the protocol prior to implementation, except when necessary to eliminate immediate hazards to the subjects.

**IBC:**
- Will review annual report after the PI submits it to the IBC.
- Will review adverse events that the PI submits to the IBC and report them to the Office of Biotechnology Activities at the NIH as appropriate.
- Will review modifications to the protocol prior to the PI submitting the modification to the IRB-HSR.

**School of Medicine Clinical Trials Office:**
- Will ensure protocol compliance by periodic reviews including monitoring of completion of Case Report Forms.

**Cancer Center Protocol Review Committee: (if applicable)**
- Will review status reports every 6 months.

**Principal Investigator**
- Submit status reports to IRB-HSR and, if applicable- the Cancer Center PRC as required. Submit with the status form to the IRB and if applicable, the Cancer Center PRC any correspondence to the FDA/NIH including the annual report regarding this protocol.
- Submit unexpected problems/ adverse event to the IRB and IBC per the protocol data and safety monitoring plan.
- Submit or confirm that the study sponsor has submitted unexpected problems and adverse events associated with the use of gene transfer product to NIH OBA.
- Submit a copy of the annual report to the IBC.
**Monitoring of this Policy**

Gene Transfer Oversight Committee: a group made up of at least one person from each of the IRB-HSR, IBC, SOM CTO, SOM Research Office, and the Cancer Center Protocol Review Committee will meet, as required, to review this policy and related compliance issues.

For additional information see http://oba.od.nih.gov/rdna/rdna.html.

**Policy History:** Implemented January 1, 2002. Revised 3/20/08; 12/10/11

Approved:

Steven T. DeKosky, MD
Vice President and Dean